Exploratory pharmacokinetic/pharmacodynamic range of tigecycline for balancing treatment effect and safety in hospital-acquired pneumonia: a retrospective cohort study
Introduction Tigecycline (TGC) is a core antibiotic for treating hospital-acquired pneumonia (HAP) caused by multidrug-resistant (MDR) bacteria, but the absence of individualized dosing guidance that balances treatment effect and safety frequently results in suboptimal efficacy or coagulation-related adverse events in...